跳至主要内容
临床试验/NCT02711163
NCT02711163已完成3 期

Evaluation of the Hypoallergenicity of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow's Milk Protein Allergy

United Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2016年4月最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
30
试验地点
1
主要终点
Percentage of infants tolerating the formula during a double blind placebo controlled food challenge

研究概览

简要总结

The aim of this study is to assess the hypoallergenicity of a new thickened extensively hydrolyzed formula, in infants with confirmed cow's milk protein allergy assessed through a double blind placebo controlled food challenge, followed by a 3-month open feeding period.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
1 Month 至 36 Months(Child)
性别
All
接受健康志愿者

入选标准

  • with cow's milk allergy confirmed by a double-blind food challenge performed in the last 2 months,
  • successfully fed an eviction diet for at least 2 weeks
  • Main Non-inclusion Criteria:
  • fed with an extensively hydrolyzed formula with no improvement of the symptoms,
  • who refused to drink an extensively hydrolyzed formula anytime prior to inclusion,
  • fed a vegetable based formula
  • fed an amino acid based formula or who should be fed with an amino acid based formula according to recommendations
  • who had an anaphylactic reaction in the past

排除标准

  • 未提供

研究组 & 干预措施

Extensively hydrolyzed formula

Experimental

Feeding extensively hydrolyzed formula

干预措施: Extensively Hydrolyzed formula (Dietary Supplement)

Amino acid formula

Placebo Comparator

Feeding amino acid formula

干预措施: Amino acid formula (Dietary Supplement)

结局指标

主要结局

Percentage of infants tolerating the formula during a double blind placebo controlled food challenge

时间窗: 7 days

次要结局

  • Regurgitation assessed through Vandenplas score(7, 45 and 90 days)
  • Abdominal pain (severity on a 4 level scale)(7, 45 and 90 days)
  • Weight expressed in z scores according to the WHO Child Growth Standards(45 and 90 days)
  • Stool consistency assessed through Bristol Stools Form Scale(7, 45 and 90 days)
  • Duration of crying over 24h(7, 45 and 90 days)
  • Urticaria (presence/absence)(7, 45 and 90 days)
  • Eczema assessed through SCORAD(7, 45 and 90 days)
  • Vomiting (weekly frequency)(7, 45 and 90 days)
  • Bloating and gas (severity on a 4 level scale)(7, 45 and 90 days)
  • Sleeping time over 24h(7, 45 and 90 days)
  • Stool frequency over 72h(7, 45 and 90 days)
  • Blood in stools (presence/absence)(7, 45 and 90 days)
  • Respiratory symptoms (severity on a 4 level scale)(7, 45 and 90 days)
  • Height expressed in z scores according to the WHO Child Growth Standards(45 and 90 days)
  • BMI expressed in z scores according to the WHO Child Growth Standards(45 and 90 days)
  • Head circumference expressed in z scores according to the WHO Child Growth Standards(45 and 90 days)
  • Number of patients with treatment emergent Adverse Events(7, 45 and 90 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验